Safety of the newer inhaled corticosteroids in childhood asthma

Pediatric Drugs

Volumn 5, Issue 7, 2003, Pages 481-504

  Randell, Tabitha L ^a   Donaghue, Kim C ^a,b   Ambler, Geoffrey R ^a   Cowell, Christopher T ^a,b   Fitzgerald, Dominic A ^a,b   Van Asperen, Peter P ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; CORTICOSTEROID; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; NEDOCROMIL; NORFLURANE;

ADRENAL DISEASE; ADRENAL INSUFFICIENCY; ASTHMA; BIOAVAILABILITY; BONE MINERALIZATION; CLINICAL TRIAL; DENTAL CARIES; DENTAL HEALTH; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG SAFETY; DYSPHONIA; FRACTURE; GROWTH DISORDER; GROWTH INHIBITION; HUMAN; MOUTH HYGIENE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THRUSH; TOOTH DISEASE;

EID: 0043124633     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200305070-00005     Document Type: Review

References (97)

1. National Institutes of Health. National asthma education and prevention program expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health, 1997. Publication no. 97-4051
2. Van Asperen PP, Mellis CM, Sly PD. The role of corticosteroids in the management of childhood asthma. The Thoracic Society of Australia and New Zealand. Med J Aust 1992; 156 (1): 48-52
3. National Asthma Council. Asthma management handbook [online]. Available from URL: www.NationalAsthma.org.au [Accessed 2003 Jun 11]
4. Calpin C, Macarthur C, Stephens D, et al. Effectiveness of prophylactic inhaled steroids in childhood asthma: a systemic review of the literature. J Allergy Clin Immunol 1997; 100 (4): 452-7
5. Allen DB. Safety of inhaled corticosteroids in children. Pediatr Pulmonol 2002; 33 (3): 208-20
6. Fabbri L, Burge PS, Croonenborgh L, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. Thorax 1993; 48 (8): 817-23
7. Ferguson AC, Spier S, Manjra A, et al. Efficacy and safety of high-dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide. J Pediatr 1999; 134 (4): 422-7
8. Hamid QA, Minshall EM. Molecular pathology of allergic disease (I): lower airway disease. J Allergy Clin Immunol 2000; 105 (1 Pt 1): 20-36
9. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998; 157 (3 Pt 2): S1-53
10. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995; 50 (2): 105-10
11. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf 2000; 23 (1): 11-33
12. Daley-Yates PT, Price AC, Sisson JR, et al. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001; 51 (5): 400-9
13. Holliday SM, Faulds D, Sorkin EM. Inhaled fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs 1994; 47 (2): 318-31
14. Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs 2001; 61 (9): 1325-50
15. Fitzgerald D. Non-compliance in adolescents with chronic lung disease: causative factors and practical approach. Paediatr Respir Rev 2001; 2 (3): 260-7
16. Couriel J. Asthma in adolescence. Paediatr Respir Rev 2003; 4 (1): 47-54
17. Newman SP, Millar AB, Lennard-Jones TR, et al. Improvement of pressurised aerosol deposition with Nebuhaler spacer device. Thorax 1984; 39 (12): 935-41
18. Feddah MR, Davies NM, Gipps EM, et al. Influence of respiratory spacer devices on aerodynamic particle size distribution and fine particle mass of beclomethasone from metered-dose inhalers. J Aerosol Med 2001; 14 (4): 477-85
19. Lipworth BJ, Jackson CM. Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate. Br J Clin Pharmacol 1999; 48 (6): 866-8
20. Pedersen S, Warner J, Wahn U, et al. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children. Pediatrics 2002; 109 (6): E92
21. Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356 (9229): 556-61
22. Harrison TW, Wisniewski A, Honour J, et al. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax 2001; 56 (3): 186-91
23. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997; 52 (39 Suppl.): 1-34
24. Toogood JH, Jennings B, Greenway RW, et al. Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J Allergy Clin Immunol 1980; 65 (2): 145-53
25. Agertoft L, Larsen FE, Pedersen S. Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. Eur Respir J 1998; 12 (1): 130-5
26. Al Dlaigan YH, Shaw L, Smith AJ. Is there a relationship between asthma and dental erosion: a case control study. Int J Paediatr Dent 2002; 12 (3): 189-200
27. McDerra EJ, Pollard MA, Curzon ME. The dental status of asthmatic British school children. Pediatr Dent 1998; 20 (4): 281-7
28. O'Sullivan EA, Curzon MEJ. Drug treatments for asthma may cause erosive tooth damage [letter]. BMJ 1998; 317 (7161): 820
29. Oelkers W. Adrenal insufficiency. N Engl J Med 1996; 335 (16): 1206-12
30. Law CM, Marchant JL, Honour JW, et al. Nocturnal adrenal suppression in asthmatic children taking inhaled beclomethasone dipropionate. Lancet 1986; I (8487): 942-4
31. Patel L, Wales JK, Kibirige MS, et al. Symptomatic adrenal insufficiency during inhaled corticosteroid treatment. Arch Dis Child 2001; 85 (4): 330-4
32. Drake AJ, Howells RJ, Shield JP, et al. Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate. BMJ 2002; 324 (7345): 1081-2
33. Todd GR, Acerini CL, Buck JJ, et al. Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate. Eur Respir J 2002; 19 (6): 1207-9
34. Holt PR, Lowndes DW, Smithies E, et al. The effect of an inhaled steroid on the hypothalamic-pituitary-adrenal axis: which tests should be used? Clin Exp Allergy 1990; 20 (2): 145-9
35. Shah A, Stanhope R, Matthew D. Hazards of pharmacological tests of growth hormone secretion in childhood. BMJ 1992; 304 (6820): 173-4
36. Galloway PJ, McNeill E, Paterson WF, et al. Safety of the insulin tolerance test. Arch Dis Child 2002; 87 (4): 354-6
37. Gonzalez-Gonzalez JG, De la Garza-Hernandez NE, Mancillas-Adame LG, et al. A high-sensitivity test in the assessment of adrenocortical insufficiency: 10 microg vs 250 microg cosyntropin dose assessment of adrenocortical insufficiency. J Endocrinol 1998; 159 (2): 275-80
38. Suliman AM, Smith TP, Labib M, et al. The low-dose ACTH test does not provide a useful assessment of the hypothalamic-pituitary-adrenal axis in secondary adrenal insufficiency. Clin Endocrinol (Oxf) 2002; 56 (4): 533-9
39. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159 (9): 941-55
40. Clavano A, Ambler GR, Cowell CT, et al. The effect of inhaled steroids on bone density and adrenal gland function in children [abstract]. In: Proceedings of the Endocrine Society of Australia 40th Annual Scientific Meeting. Melbourne (VIC): The Endocrine Society of Australia, 1997: 147
41. Fitzgerald D, Van Asperen P, Mellis C, et al. Fluticasone propionate 750 micrograms/day versus beclomethasone dipropionate 1500 micrograms/day: comparison of efficacy and adrenal function in paediatric asthma. Thorax 1998; 53 (8): 656-61
42. Kannisto S, Korppi M, Remes K, et al. Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab 2000; 85 (2): 652-7
43. Lipworth BJ, Clark DJ, McFarlane LC. Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children. Thorax 1997; 52 (8): 686-9
44. Barnes NC, Hallett C, Harris TA. Clinical experience with fluticasone propionate in asthma: a meta- analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med 1998; 92 (1): 95-104
45. Fowler SJ, Orr LC, Wilson AM, et al. Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. Br J Clin Pharmacol 2001; 52 (1): 93-5
46. Davies RJ, Stampone P, O'Connor BJ. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med 1998; 92 Suppl. A: 23-31
47. Gross G, Thompson PJ, Chervinsky P, et al. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma. Chest 1999; 115 (2): 343-51
48. Fireman P, Prenner BM, Vincken W, et al. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Ann Allergy Asthma Immunol 2001; 86 (5): 557-65
49. Affrime MB, Kosoglou T, Thonoor CM, et al. Mometasone furoate has minimal effects on the hypothalamic-pituitary- adrenal axis when delivered at high doses. Chest 2000; 118 (6): 1538-46
50. Allen DB, Bronsky EA, LaForce CF, et al. Growth in asthmatic children treated with fluticasone propionate. Fluticasone Propionate Asthma Study Group. J Pediatr 1998; 132 (3 Pt 1): 472-7
51. Wong J, Black P. Acute adrenal insufficiency associated with high dose inhaled steroids [letter]. BMJ 1992; 304 (6839): 1415
52. Zwaan CM, Odink RJ, Delemarre-van de Waal HA, et al. Acute adrenal insufficiency after discontinuation of inhaled corticosteroid therapy. Lancet 1992; 340 (8830): 1289-90
53. Taylor AV, Laoprasert N, Zimmerman D, et al. Adrenal suppression secondary to inhaled fluticasone propionate. Ann Allergy Asthma Immunol 1999; 83 (1): 68-70
54. Todd GR, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87 (6): 457-61
55. Macdessi JS, Randell TL, Donaghue KC, et al. Adrenal crises in children treated with high-dose inhaled corticosteroids for asthma. Med J Aust 2003; 178 (5): 214-6
56. The General Practioner in Asthma Group, the British Association of Accident and Emergency Medicine, the British Paediatric Respiratory Society, and the Royal College of Paediatrics and Child Health. Asthma in adults and school children. Thorax 1997; 52 Suppl. 1: S2-5
57. The General Practioner in Asthma Group, the British Association of Accident and Emergency Medicine, the British Paediatric Respiratory Society, and the Royal College of Paediatrics and Child Health. Asthma in adults and school children. Thorax 1997; 52 Suppl. 1: S20
58. Tanner JM, Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985; 107 (3): 317-29
59. Allen DB. Inhaled corticosteroid therapy for asthma in preschool children: growth issues. Pediatrics 2002; 109 (2 Suppl.): 373-80
60. Abu EO, Horner A, Kusec V, et al. The localization of the functional glucocorticoid receptor alpha in human bone. J Clin Endocrinol Metab 2000; 85 (2): 883-9
61. Russell G. Asthma and growth. Arch Dis Child 1993; 69 (6): 695-8
62. Martin AJ, Landau LI, Phelan PD. The effect on growth of childhood asthma. Acta Paediatr Scand 1981; 70 (5): 683-8
63. Balfour-Lynn L. Growth and childhood asthma. Arch Dis Child 1986; 61 (11): 1049-55
64. Shaw NJ, Fraser NC, Weller PH. Asthma treatment and growth. Arch Dis Child 1997; 77 (4): 284-6
65. de Benedictis FM, Teper A, Green RJ, et al. Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial. Arch Pediatr Adolesc Med 2001; 155 (11): 1248-54
66. Allen DB. Limitations of short-term studies in predicting long-term adverse effects of inhaled corticosteroids. Allergy 1999; 54 Suppl. 49: 29-34
67. Wolthers OD, Hansen M, Juul A, et al. Knemometry, urine cortisol excretion, and measures of the insulin-like growth factor axis and collagen turnover in children treated with inhaled glucocorticosteroids. Pediatr Res 1997; 41 (1): 44-50
68. Agertoft L, Pedersen S. Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study. Eur Respir J 1997; 10 (7): 1507-12
69. Visser MJ, van Aalderen WM, Elliott BM, et al. Short-term growth in asthmatic children using fluticasone propionate. Chest 1998; 113 (3): 584-6
70. Anhoj J, Bisgaard AM, Bisgaard H. Systemic activity of inhaled steroids in 1- to 3-year-old children with asthma. Pediatrics 2002; 109 (3): E40
71. Agertoft L, Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol 1999; 104 (5): 948-52
72. Simons ICE. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. N Engl J Med 1997; 337 (23): 1659-65
73. Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics 2000; 106 (1): E8
74. Sharek PJ, Bergman DA, Ducharme F. Beclomethasone for asthma in children: effects on linear growth (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 4. Oxford: Update Software, 2002
75. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000; 343 (15): 1054-63
76. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343 (15): 1064-9
77. Todd G, Dunlop K, McNaboe J, et al. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 1996; 348 (9019): 27-9
78. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000; 105 (2): E22
79. Jonasson G, Carlsen KH, Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child 2000; 83 (4): 330-3
80. Wolthers OD, Allen DB. Inhaled corticosteroids, growth, and compliance. N Engl J Med 2002; 347 (15): 1210-1
81. Leonard MB, Zemel BS. Current concepts in pediatric bone disease. Pediatr Clin North Am 2002; 49 (1): 143-73
82. Reilly SM, Hambleton G, Adams JE, et al. Bone density in asthmatic children treated with inhaled corticosteroids. Arch Dis Child 2001; 84 (2): 183-4
83. Lu PW, Briody JN, Ogle GD, et al. Bone mineral density of total body, spine, and femoral neck in children and young adults: a cross-sectional and longitudinal study. J Bone Miner Res 1994; 9 (9): 1451-8
84. Gilsanz V, Kovanlikaya A, Costin G, et al. Differential effect of gender on the sizes of the bones in the axial and appendicular skeletons [published erratum appears in J Clin Endocrinol Metab 1997 Jul; 82 (7): 2274]. J Clin Endocrinol Metab 1997; 82 (5): 1603-7
85. Schoenau E, Neu CM, Rauch F, et al. The development of bone strength at the proximal radius during childhood and adolescence. J Clin Endocrinol Metab 2001; 86 (2): 613-8
86. Lu PW, Cowell CT, LLoyd-Jones SA, et al. Volumetric bone mineral density in normal subjects, aged 5-27 years. J Clin Endocrinol Metab 1996; 81 (4): 1586-90
87. Kroger H, Kotaniemi A, Vainio P, et al. Bone densitometry of the spine and femur in children by dual-energy x-ray absorptiometry [published erratum appears in Bone Miner 1992 Jun; 17 (3): 429]. Bone Miner 1992; 17 (1): 75-85
88. Sievanen H, Kannus P, Nieminen V, et al. Estimation of various mechanical characteristics of human bones using dual energy X-ray absorptiometry: methodology and precision. Bone 1996; 18 (1 Suppl.): 17-27S
89. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992; 7 (2): 137-45
90. Sorva R, Turpeinen M, Juntunen-Backman K, et al. Effects of inhaled budesonide on serum markers of bone metabolism in children with asthma. J Allergy Clin Immunol 1992; 90 (5): 808-15
91. Wong CA, Walsh LJ, Smith CJ, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000; 355 (9213): 1399-403
92. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001; 345 (13): 941-7
93. Baraldi E, Bollini MC, De Marchi A, et al. Effect of beclomethasone dipropionate on bone mineral content assessed by x-ray densitometry in asthmatic children: a longitudinal evaluation. Eur Respir J 1994; 7 (4): 710-4
94. Harris M, Hauser S, Nguyen TV, et al. Bone mineral density in prepubertal asthmatics receiving corticosteroid treatment. J Paediatr Child Health 2001; 37 (1): 67-71
95. Gregson RK, Rao R, Murrills AJ, et al. Effect of inhaled corticosteroids on bone mineral density in childhood asthma: comparison of fluticasone propionate with beclomethasone dipropionate. Osteoporos Int 1998; 8 (5): 418-22
96. van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001; 16 (3): 581-8
97. Ma DQ, Jones G. Clinical risk factors but not bone density are associated with prevalent fractures in prepubertal children. J Paediatr Child Health 2002; 38 (5): 497-500